Vion Pharmaceuticals' New Drug Application For Onrigin(TM)Accepted For Review By The FDA (Medical News Today)
Vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company had previously announced the filing of the NDA with the FDA in February 2009.

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation For Ovarian Cancer In The USA (Medical News Today)
Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail additional assistance from FDA to expedite and optimize drug development and upon approval a seven year market exclusivity is granted.

American Biotech Labs(R) Obtains FDA Approval For New Wound Care Gel Product (Medical News Today)
American Biotech Labs, LLC (ABL), developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(R), announced that the company has been granted formal approval by the U.S. Food and Drug Administration (FDA) to market its ASAP Wound Dressing Gel throughout the United States.